PL375021A1 - Podstawiony (tiazol-2-ilo)amid lub-sulfoamid jakoaktywatory glukokinazy użyteczne w leczeniu cukrzycy typu 2 - Google Patents
Podstawiony (tiazol-2-ilo)amid lub-sulfoamid jakoaktywatory glukokinazy użyteczne w leczeniu cukrzycy typu 2Info
- Publication number
- PL375021A1 PL375021A1 PL03375021A PL37502103A PL375021A1 PL 375021 A1 PL375021 A1 PL 375021A1 PL 03375021 A PL03375021 A PL 03375021A PL 37502103 A PL37502103 A PL 37502103A PL 375021 A1 PL375021 A1 PL 375021A1
- Authority
- PL
- Poland
- Prior art keywords
- thiazol
- sulfonamide
- diabetes
- amide
- substituted
- Prior art date
Links
- RAIPHJJURHTUIC-UHFFFAOYSA-N 1,3-thiazol-2-amine Chemical class NC1=NC=CS1 RAIPHJJURHTUIC-UHFFFAOYSA-N 0.000 title 1
- 239000012190 activator Substances 0.000 title 1
- 229940124530 sulfonamide Drugs 0.000 title 1
- 150000003456 sulfonamides Chemical class 0.000 title 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/50—Nitrogen atoms bound to hetero atoms
- C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41586002P | 2002-10-03 | 2002-10-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL375021A1 true PL375021A1 (pl) | 2005-11-14 |
Family
ID=32469191
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL03375021A PL375021A1 (pl) | 2002-10-03 | 2003-10-02 | Podstawiony (tiazol-2-ilo)amid lub-sulfoamid jakoaktywatory glukokinazy użyteczne w leczeniu cukrzycy typu 2 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US7812167B2 (pl) |
| EP (1) | EP1549626A1 (pl) |
| JP (1) | JP2006509774A (pl) |
| KR (1) | KR20050074959A (pl) |
| CN (2) | CN101805358A (pl) |
| AU (1) | AU2003302279B2 (pl) |
| BR (1) | BR0314864A (pl) |
| CA (1) | CA2498089A1 (pl) |
| CO (1) | CO5721000A2 (pl) |
| EC (1) | ECSP055705A (pl) |
| HK (1) | HK1079788A1 (pl) |
| MX (1) | MXPA05003559A (pl) |
| NO (1) | NO20052159L (pl) |
| NZ (1) | NZ539013A (pl) |
| PL (1) | PL375021A1 (pl) |
| RU (1) | RU2005113713A (pl) |
| WO (1) | WO2004050645A1 (pl) |
| ZA (1) | ZA200501532B (pl) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0102299D0 (sv) | 2001-06-26 | 2001-06-26 | Astrazeneca Ab | Compounds |
| SE0102764D0 (sv) | 2001-08-17 | 2001-08-17 | Astrazeneca Ab | Compounds |
| PL375021A1 (pl) | 2002-10-03 | 2005-11-14 | Novartis Ag | Podstawiony (tiazol-2-ilo)amid lub-sulfoamid jakoaktywatory glukokinazy użyteczne w leczeniu cukrzycy typu 2 |
| GB0226931D0 (en) | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
| GB0226930D0 (en) | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
| PL378117A1 (pl) | 2003-02-11 | 2006-03-06 | Prosidion Limited | Tricyklopodstawione związki amidowe |
| EP1648422A4 (en) * | 2003-07-28 | 2007-09-19 | Reddys Lab Inc Dr | TREATMENT AND PREVENTION OF CARDIOVASCULAR ACCIDENTS |
| US7781451B2 (en) | 2004-04-02 | 2010-08-24 | Novartis Ag | Thiazolopyridine derivatives, pharmaceut ical conditions containing them and methods of treating glucokinase mediated conditions |
| PT1735322E (pt) * | 2004-04-02 | 2012-01-12 | Novartis Ag | Derivados de sulfonamido-tiazolopiridina como activadores de glucoquinase úteis para o tratamento de diabetes de tipo 2 |
| MX2007001650A (es) * | 2004-08-12 | 2007-07-13 | Prosidion Ltd | Fenilacetamidas substituidas y su uso como activadores de glucocinasa. |
| BRPI0612582A2 (pt) * | 2005-07-01 | 2010-11-23 | Novartis Ag | combinação de compostos orgánicos |
| KR20110084339A (ko) | 2005-07-09 | 2011-07-21 | 아스트라제네카 아베 | 당뇨병 치료에 있어 ｇｌｋ 활성화제로서 사용하기 위한 헤테로아릴 벤즈아미드 유도체 |
| AU2006285834A1 (en) | 2005-08-31 | 2007-03-08 | Astellas Pharma Inc. | Thiazole derivative |
| JP2007063225A (ja) | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | イミダゾピリジン化合物 |
| GT200600429A (es) * | 2005-09-30 | 2007-04-30 | Compuestos organicos | |
| GT200600428A (es) * | 2005-09-30 | 2007-05-21 | Compuestos organicos | |
| CA2626475A1 (en) * | 2005-11-03 | 2007-05-10 | Prosidion Limited | Tricyclo substituted amides |
| US20070116756A1 (en) * | 2005-11-23 | 2007-05-24 | Dr. Reddy's Laboratories Limited | Stable pharmaceutical compositions |
| JP5236499B2 (ja) * | 2006-01-27 | 2013-07-17 | アレイ バイオファーマ、インコーポレイテッド | グルコキナーゼ活性化剤 |
| EP2001875A2 (en) | 2006-03-08 | 2008-12-17 | Takeda San Diego, Inc. | Glucokinase activators |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| EP2049518B1 (en) | 2006-05-31 | 2011-08-31 | Takeda San Diego, Inc. | Indazole and isoindole derivatives as glucokinase activating agents. |
| JP2009544648A (ja) | 2006-07-24 | 2009-12-17 | エフ．ホフマン−ラ ロシュ アーゲー | グルコキナーゼ活性化剤としてのピラゾール類 |
| JP5419706B2 (ja) | 2006-12-20 | 2014-02-19 | タケダ カリフォルニア インコーポレイテッド | グルコキナーゼアクチベーター |
| TW200831081A (en) * | 2006-12-25 | 2008-08-01 | Kyorin Seiyaku Kk | Glucokinase activator |
| WO2008084872A1 (ja) | 2007-01-10 | 2008-07-17 | Mitsubishi Tanabe Pharma Corporation | ヒドラゾン誘導体 |
| US8034819B2 (en) * | 2007-03-07 | 2011-10-11 | Kyorin Pharmaceutical Co., Ltd. | Glucokinase activator |
| WO2008116107A2 (en) | 2007-03-21 | 2008-09-25 | Takeda San Diego, Inc. | Piperazine derivatives as glucokinase activators |
| EA019104B1 (ru) | 2007-09-21 | 2014-01-30 | Эррей Биофарма Инк. | Активаторы глюкокиназы |
| AU2009205070A1 (en) | 2008-01-18 | 2009-07-23 | Astellas Pharma Inc. | Phenyl acetamide derivative |
| US8258134B2 (en) | 2008-04-16 | 2012-09-04 | Hoffmann-La Roche Inc. | Pyridazinone glucokinase activators |
| US7741327B2 (en) | 2008-04-16 | 2010-06-22 | Hoffmann-La Roche Inc. | Pyrrolidinone glucokinase activators |
| CN102089291B (zh) | 2008-04-28 | 2016-08-17 | 杏林制药株式会社 | 环戊基丙烯酰胺衍生物 |
| JP5513492B2 (ja) | 2008-05-16 | 2014-06-04 | タケダ カリフォルニア インコーポレイテッド | グルコキナーゼ活性剤 |
| US8410284B2 (en) | 2008-10-22 | 2013-04-02 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
| WO2010051206A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| US8222416B2 (en) | 2009-12-14 | 2012-07-17 | Hoffmann-La Roche Inc. | Azaindole glucokinase activators |
| JP2013520502A (ja) | 2010-02-25 | 2013-06-06 | メルク・シャープ・エンド・ドーム・コーポレイション | 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体 |
| CN102241644B (zh) * | 2010-05-10 | 2013-07-17 | 天津药物研究院 | α-氨基-3-芳基丙酰胺基噻唑衍生物、其制备方法和用途 |
| CA2826649C (en) | 2011-02-25 | 2016-07-26 | Merck Sharp & Dohme Corp. | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
| WO2012138776A1 (en) * | 2011-04-05 | 2012-10-11 | Amgen Inc. | Benzodioxepine and benzodioxine compounds that interact with glucokinase regulatory protein for the treatment of diabetes |
| US8921576B2 (en) | 2011-10-19 | 2014-12-30 | Kowa Company, Ltd. | Spiroindoline compound, and medicinal agent comprising same |
| US20140045746A1 (en) | 2012-08-02 | 2014-02-13 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| JP2016516004A (ja) | 2013-02-22 | 2016-06-02 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 抗糖尿病二環式化合物 |
| WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| WO2018106518A1 (en) | 2016-12-06 | 2018-06-14 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
| WO2018118670A1 (en) | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6040321A (en) * | 1997-11-12 | 2000-03-21 | Bristol-Myers Squibb Company | Aminothiazole inhibitors of cyclin dependent kinases |
| GB9823871D0 (en) * | 1998-10-30 | 1998-12-23 | Pharmacia & Upjohn Spa | 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents |
| US6610846B1 (en) | 1999-03-29 | 2003-08-26 | Hoffman-La Roche Inc. | Heteroaromatic glucokinase activators |
| RU2242469C2 (ru) * | 1999-03-29 | 2004-12-20 | Ф.Хоффманн-Ля Рош Аг | Активаторы глюкокиназы |
| US6320050B1 (en) | 1999-03-29 | 2001-11-20 | Hoffmann-La Roche Inc. | Heteroaromatic glucokinase activators |
| HK1046139B (zh) | 1999-03-29 | 2004-12-10 | 霍夫曼-拉罗奇有限公司 | 葡糖激酶活化剂 |
| US6353111B1 (en) * | 1999-12-15 | 2002-03-05 | Hoffmann-La Roche Inc. | Trans olefinic glucokinase activators |
| EP1282612B1 (en) | 2000-05-03 | 2004-12-29 | F. Hoffmann-La Roche Ag | Alkynyl phenyl heteroaromatic glucokinase activators |
| ATE304011T1 (de) | 2000-05-03 | 2005-09-15 | Hoffmann La Roche | Hydantoin-enthaltende glucokinase aktivatoren |
| US6489485B2 (en) | 2000-05-08 | 2002-12-03 | Hoffmann-La Roche Inc. | Para-amine substituted phenylamide glucokinase activators |
| BR0110704A (pt) | 2000-05-08 | 2003-01-28 | Hoffmann La Roche | Fenil - acetamidas substituìdas e seu uso como ativadores de glicocinase |
| MXPA02010795A (es) * | 2000-05-08 | 2003-03-27 | Hoffmann La Roche | Activadores de glucocinasa de fenilamida sustituida por para-amino. |
| JP2001333778A (ja) * | 2000-05-26 | 2001-12-04 | Akihiko Shiraishi | グルコキナーゼ活性化物質、糖尿病治療薬及び抗肥満薬 |
| CA2416229C (en) | 2000-07-20 | 2007-09-18 | F. Hoffmann-La Roche Ag | Alpha-acyl and alpha-heteroatom-substituted benzene acetamide glucokinase activators |
| JP2002053566A (ja) * | 2000-08-11 | 2002-02-19 | Japan Tobacco Inc | チアゾール化合物及びその医薬用途 |
| US6369232B1 (en) | 2000-08-15 | 2002-04-09 | Hoffmann-La Roche Inc. | Tetrazolyl-phenyl acetamide glucokinase activators |
| US6433188B1 (en) | 2000-12-06 | 2002-08-13 | Wendy Lea Corbett | Fused heteroaromatic glucokinase activators |
| EP1341774B1 (en) * | 2000-12-06 | 2006-02-01 | F. Hoffmann-La Roche Ag | Fused heteroaromatic glucokinase activators |
| US6482951B2 (en) | 2000-12-13 | 2002-11-19 | Hoffmann-La Roche Inc. | Isoindolin-1-one glucokinase activators |
| SE0102299D0 (sv) | 2001-06-26 | 2001-06-26 | Astrazeneca Ab | Compounds |
| SE0102764D0 (sv) | 2001-08-17 | 2001-08-17 | Astrazeneca Ab | Compounds |
| EP1453541A1 (en) | 2001-12-03 | 2004-09-08 | Novo Nordisk A/S | Use of a glucokinase activator in combination with a glucagon antagonist for treating type 2 diabetes |
| US6911545B2 (en) | 2001-12-19 | 2005-06-28 | Hoffman-La Roche Inc. | Crystals of glucokinase and methods of growing them |
| KR101018318B1 (ko) | 2001-12-21 | 2011-03-04 | 노보 노르디스크 에이/에스 | Ｇｋ 활성제로서의 아미드 유도체 |
| WO2003080585A1 (en) | 2002-03-26 | 2003-10-02 | Banyu Pharmaceutical Co., Ltd. | Novel aminobenzamide derivative |
| BR0309546A (pt) | 2002-04-26 | 2005-02-15 | Hoffmann La Roche | Composto, composição farmacêutica que compreende o mesmo, processo para a sua preparação e utilização e método para tratamento profilático ou terapêutico de diabetes do tipo ii |
| AU2003235307A1 (en) | 2002-05-16 | 2003-12-02 | Banyu Pharmaceutical Co., Ltd. | Crystal of glucokinase protein, and method for drug design using the crystal |
| CA2744893A1 (en) | 2002-06-27 | 2004-01-08 | Novo Nordisk A/S | Aryl carbonyl derivatives as glucokinase activators |
| ES2293005T3 (es) * | 2002-10-03 | 2008-03-16 | F. Hoffmann-La Roche Ag | Indol-3-carboxamidas como activadores de la glucocinasa. |
| PL375021A1 (pl) | 2002-10-03 | 2005-11-14 | Novartis Ag | Podstawiony (tiazol-2-ilo)amid lub-sulfoamid jakoaktywatory glukokinazy użyteczne w leczeniu cukrzycy typu 2 |
| MY141521A (en) | 2002-12-12 | 2010-05-14 | Hoffmann La Roche | 5-substituted-six-membered heteroaromatic glucokinase activators |
| WO2004063194A1 (en) | 2003-01-06 | 2004-07-29 | Eli Lilly And Company | Heteroaryl compounds |
| WO2004063179A1 (en) | 2003-01-06 | 2004-07-29 | Eli Lilly And Company | Substituted arylcyclopropylacetamides as glucokinase activators |
| JP4621198B2 (ja) | 2003-02-11 | 2011-01-26 | プロシディオン・リミテッド | トリ（シクロ）置換アミドグルコキナーゼ活性化化合物 |
| PL378117A1 (pl) | 2003-02-11 | 2006-03-06 | Prosidion Limited | Tricyklopodstawione związki amidowe |
| BRPI0407283A (pt) | 2003-02-13 | 2006-01-31 | Banyu Pharma Co Ltd | Composto, composição farmacêutica, e, agente ativador de glucoquinase, agentes terapêuticos e/ou agentes preventivos para diabetes melito e obesidade |
| WO2004076420A1 (ja) | 2003-02-26 | 2004-09-10 | Banyu Pharmaceutical Co., Ltd. | ヘテロアリールカルバモイルベンゼン誘導体 |
| EP1532980A1 (en) | 2003-11-24 | 2005-05-25 | Novo Nordisk A/S | N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes |
| PT1735322E (pt) * | 2004-04-02 | 2012-01-12 | Novartis Ag | Derivados de sulfonamido-tiazolopiridina como activadores de glucoquinase úteis para o tratamento de diabetes de tipo 2 |
| US7781451B2 (en) * | 2004-04-02 | 2010-08-24 | Novartis Ag | Thiazolopyridine derivatives, pharmaceut ical conditions containing them and methods of treating glucokinase mediated conditions |
| EA012204B1 (ru) | 2004-04-21 | 2009-08-28 | Прозидион Лимитед | Три(цикло)замещённые амидные соединения |
| MX2007001650A (es) | 2004-08-12 | 2007-07-13 | Prosidion Ltd | Fenilacetamidas substituidas y su uso como activadores de glucocinasa. |
| AU2005311269B2 (en) | 2004-12-03 | 2011-11-10 | Transtech Pharma, Inc. | Heteroaromatic glucokinase activators |
| GT200600429A (es) | 2005-09-30 | 2007-04-30 | Compuestos organicos | |
| GT200600428A (es) * | 2005-09-30 | 2007-05-21 | Compuestos organicos |
-
2003
- 2003-10-02 PL PL03375021A patent/PL375021A1/pl not_active Application Discontinuation
- 2003-10-02 CN CN201010145133A patent/CN101805358A/zh active Pending
- 2003-10-02 MX MXPA05003559A patent/MXPA05003559A/es active IP Right Grant
- 2003-10-02 KR KR1020057005672A patent/KR20050074959A/ko not_active Withdrawn
- 2003-10-02 US US10/529,670 patent/US7812167B2/en not_active Expired - Fee Related
- 2003-10-02 WO PCT/EP2003/010977 patent/WO2004050645A1/en not_active Ceased
- 2003-10-02 RU RU2005113713/04A patent/RU2005113713A/ru not_active Application Discontinuation
- 2003-10-02 NZ NZ539013A patent/NZ539013A/en unknown
- 2003-10-02 AU AU2003302279A patent/AU2003302279B2/en not_active Ceased
- 2003-10-02 CA CA002498089A patent/CA2498089A1/en not_active Abandoned
- 2003-10-02 BR BR0314864-5A patent/BR0314864A/pt not_active Application Discontinuation
- 2003-10-02 EP EP03810838A patent/EP1549626A1/en not_active Withdrawn
- 2003-10-02 CN CNA2003801008797A patent/CN1703408A/zh active Pending
- 2003-10-02 JP JP2004556081A patent/JP2006509774A/ja active Pending
- 2003-10-02 HK HK05112147.2A patent/HK1079788A1/zh unknown
-
2005
- 2005-02-22 ZA ZA200501532A patent/ZA200501532B/xx unknown
- 2005-03-28 EC EC2005005705A patent/ECSP055705A/es unknown
- 2005-03-30 CO CO05027999A patent/CO5721000A2/es not_active Application Discontinuation
- 2005-05-02 NO NO20052159A patent/NO20052159L/no not_active Application Discontinuation
-
2010
- 2010-09-03 US US12/875,215 patent/US20100330021A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| NZ539013A (en) | 2007-05-31 |
| US20100330021A1 (en) | 2010-12-30 |
| AU2003302279A1 (en) | 2004-06-23 |
| KR20050074959A (ko) | 2005-07-19 |
| ECSP055705A (es) | 2005-05-30 |
| CO5721000A2 (es) | 2007-01-31 |
| US7812167B2 (en) | 2010-10-12 |
| JP2006509774A (ja) | 2006-03-23 |
| BR0314864A (pt) | 2005-08-02 |
| CN101805358A (zh) | 2010-08-18 |
| AU2003302279B2 (en) | 2008-06-12 |
| ZA200501532B (en) | 2006-11-29 |
| CN1703408A (zh) | 2005-11-30 |
| NO20052159L (no) | 2005-05-02 |
| WO2004050645A8 (en) | 2005-05-19 |
| EP1549626A1 (en) | 2005-07-06 |
| HK1079788A1 (zh) | 2006-04-13 |
| CA2498089A1 (en) | 2004-06-17 |
| US20050282851A1 (en) | 2005-12-22 |
| WO2004050645A1 (en) | 2004-06-17 |
| MXPA05003559A (es) | 2005-06-03 |
| RU2005113713A (ru) | 2006-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200501532B (en) | Substituted (thiazol-2-YL)-amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes | |
| IL178151A0 (en) | Sulfonamide-thiazolpyridine derivatives as glucokinase activators useful in the treatment of type 2 diabetes | |
| PL373701A1 (pl) | Podstawione fenyloacetamidy i ich zastosowanie jako aktywatorów glukokinazy | |
| PL373502A1 (pl) | Tripodstawione związki heteroarylowe oraz sposobyich wytwarzania i stosowania | |
| IL164455A0 (en) | Heterocyclic compounds and pharmaceutical compositions containing the same | |
| PL372888A1 (pl) | Modyfikowane i stabilizowane propeptydy GDF i ichzastosowanie | |
| PT1633333E (pt) | Uso de estabilizadores hif alfa para a melhoria da eritropoiese | |
| SI1575597T1 (sl) | Uporaba rimeksolona pri zdravljenju suhega očesa | |
| EG24124A (en) | Pharmaceutical compositions for the treatment of type-II diabetes mellitus | |
| PL375149A1 (pl) | Indolo-3-karboksyamidy jako aktywatory glukokinazy (GK) | |
| GB0229742D0 (en) | Novel compounds and uses thereof | |
| GB0201743D0 (en) | Cosmetic or personal care composition | |
| AU2003232536A1 (en) | Microcapsules containing biomedical materials | |
| DE60121951D1 (de) | Charakterisierung nichtlinearen Verhaltens | |
| TWI319762B (en) | 1,7,8-trifluoro-2-naphthol and manufacturing methods for liquid crystal compositions containing the same | |
| EP1539153A4 (en) | THERAPEUTIC TREATMENT OF METABOLIC SYNDROME AND FOR DIABETES TYPE 2 | |
| DE60326190D1 (de) | des Körpers | |
| PL375627A1 (pl) | Pochodne 2-pirolidyn-2-ylo[1,3,4]-oksadiazolu i ich zastosowanie jako środków przeciwdepresyjnych | |
| GB2389645B (en) | Improvements in or relating to the treatment of molten materials | |
| GB0305953D0 (en) | Personal cleaning composition | |
| PL1786759T3 (pl) | Nowe pochodne 3,5-seko-4-norcholestanowe i ich zastosowanie | |
| FI20040837A0 (fi) | Taajuusmuuttujan verkkosillan ohjaus | |
| ATE395937T1 (de) | Zur erhöhung der konzentration von radioaktivem biotin bei der pretargeted radioimmuntherapie wirksame avidindimere | |
| AU2003291461A8 (en) | Compositions for diabetes treatment and prophylaxis | |
| PL373800A1 (pl) | Monoterapia do leczenia stwardnienia zanikowego bocznego za pomocą inhibitorów cyklooksygenazy 2 (COX 2) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |